• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Friday

    12/1/23 10:22:10 AM ET
    $BNTX
    $CC
    $ESTC
    $IMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Major Chemicals
    Industrials
    Get the next $BNTX alert in real time by email
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. RBC Capital increased The Chemours Company (NYSE:CC) price target from $28 to $40. RBC Capital analyst Arun Viswanathan upgraded the stock from Sector Perform to Outperform. Chemours shares rose 2.7% to close at $27.43 on Thursday. See how other analysts view this stock. Guggenheim raised the price target for ImmunoGen, Inc. (NASDAQ:IMGN) from $25 to $31. Guggenheim analyst Michael Schmidt downgraded the stock from Buy to Neutral. ImmunoGen shares gained 82.8% to close at $29.35 on Thursday. See how other analysts view this stock. Keybanc cut the price target for Marvell Technology, Inc. (NASDAQ:MRVL) from $80 to $70. Keybanc analyst John Vinh maintained an Overweight rating. Marvell Technology shares fell 0.7% to close at $55.73 on Thursday. See how other analysts view this stock. Citigroup boosted the price target for Lululemon Athletica Inc. (NASDAQ:LULU) from $450 to $520. Citigroup analyst Paul Lejuez maintained a Buy rating. Lululemon shares gained 1.9% to close at $446.80 on Thursday. See how other analysts view this stock. JP Morgan cut the price target for BioNTech SE (NASDAQ:BNTX) from $106 to $99. JP Morgan analyst Jessica Fye downgraded the stock from Neutral to Underweight. BioNTech shares rose 1.2% to close at $100.41 on Thursday. See how other analysts view this stock. UBS increased MarketWise, Inc. (NASDAQ:MKTW) price target from $3 to $3.5. UBS analyst Alex Kramm downgraded the stock from Buy to Neutral. MarketWise shares fell 3.9% to close at $3.19 on Thursday. See how other analysts view this stock. Citigroup raised Ulta Beauty, Inc. (NASDAQ:ULTA) price target from $440 to $485. Citigroup analyst Kelly Crago maintained a Neutral rating. Ulta Beauty shares rose 1.4% to close at $425.99 on Thursday. See how other analysts view this stock. Wells Fargo boosted Elastic N.V. (NYSE:ESTC) price target from $70 to $115. Wells Fargo analyst Andrew Nowinski upgraded the stock from Equal-Weight to Overweight. Elastic shares rose 0.9% to close at $80.36 on Thursday. See how other analysts view this stock. Telsey Advisory Group boosted PVH Corp. (NYSE:PVH) price target from $102 to $111. Telsey Advisory Group analyst Dana Telsey maintained an Outperform rating. PVH shares rose 6.8% to close at $97.78 on Thursday. See how other analysts view this stock. Telsey Advisory Group boosted Victoria's Secret & Co. (NYSE:VSCO) price target from $21 to $29. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Victoria's Secret shares gained 14.3% to close at $26.95 on Thursday. See how other analysts view this stock.
    Get the next $BNTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNTX
    $CC
    $ESTC
    $IMGN

    CompanyDatePrice TargetRatingAnalyst
    BioNTech SE
    $BNTX
    2/2/2026$113.00Outperform → Market Perform
    Leerink Partners
    Ulta Beauty Inc.
    $ULTA
    1/21/2026$790.00Outperform → Strong Buy
    Raymond James
    BioNTech SE
    $BNTX
    1/16/2026$142.00Neutral → Buy
    Goldman
    Marvell Technology Inc.
    $MRVL
    1/15/2026$105.00Outperform
    RBC Capital Mkts
    Ulta Beauty Inc.
    $ULTA
    1/14/2026$700.00Hold
    Jefferies
    PVH Corp.
    $PVH
    1/14/2026$85.00Buy
    Jefferies
    lululemon athletica inc.
    $LULU
    1/8/2026Hold
    Deutsche Bank
    Ulta Beauty Inc.
    $ULTA
    1/8/2026Buy
    Deutsche Bank
    More analyst ratings

    $BNTX
    $CC
    $ESTC
    $IMGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Fin. & Operating Officer Sekella Scott covered exercise/tax liability with 2,061 shares, decreasing direct ownership by 6% to 30,584 units (SEC Form 4)

    4 - Victoria's Secret & Co. (0001856437) (Issuer)

    2/4/26 4:50:46 PM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Chairman of the Board and CEO Murphy Matthew J covered exercise/tax liability with 72,765 shares and converted options into 144,662 shares, increasing direct ownership by 27% to 340,106 units (SEC Form 4)

    4 - Marvell Technology, Inc. (0001835632) (Issuer)

    2/4/26 3:34:20 PM ET
    $MRVL
    Semiconductors
    Technology

    Amendment: Chief Financial Officer Meintjes Willem A converted options into 47,304 shares and covered exercise/tax liability with 19,664 shares, increasing direct ownership by 18% to 184,111 units (SEC Form 4)

    4/A - Marvell Technology, Inc. (0001835632) (Issuer)

    1/30/26 5:57:02 PM ET
    $MRVL
    Semiconductors
    Technology

    $BNTX
    $CC
    $ESTC
    $IMGN
    SEC Filings

    View All

    SEC Form 144 filed by BioNTech SE

    144 - BioNTech SE (0001776985) (Subject)

    2/12/26 8:17:13 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Marvell Technology Inc.

    S-8 - Marvell Technology, Inc. (0001835632) (Filer)

    2/10/26 5:29:40 PM ET
    $MRVL
    Semiconductors
    Technology

    SEC Form 8-K filed by Marvell Technology Inc.

    8-K - Marvell Technology, Inc. (0001835632) (Filer)

    2/6/26 6:02:57 AM ET
    $MRVL
    Semiconductors
    Technology

    $BNTX
    $CC
    $ESTC
    $IMGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Victoria's Secret & Co. Invites You to Listen to the Fourth Quarter 2025 Earnings Call

    REYNOLDSBURG, Ohio, Feb. 12, 2026 (GLOBE NEWSWIRE) -- In conjunction with the Victoria's Secret & Co. (NYSE:VSCO) fourth quarter 2025 earnings release, you are invited to listen to a live webcast of the conference call on Thursday, March 5th at 8:30 a.m. ET with Victoria's Secret & Co. executives. The earnings release and related financial information detailing the company's fourth quarter results are expected to be issued approximately one hour prior to the start of the live webcast. The earnings release and related financial information will be available on our website at victoriassecretandco.com/investors. What:Victoria's Secret & Co. Fourth Quarter 2025 Earnings Conference Call Webcast

    2/12/26 7:00:00 AM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Marvell Completes Acquisition of XConn Technologies

    Marvell Technology, Inc. (NASDAQ:MRVL), a leader in data infrastructure semiconductor solutions, today announced that it has completed its previously announced acquisition of XConn Technologies ("XConn"), a provider of advanced PCIe and CXL switching silicon. The acquisition expands Marvell's switching portfolio with XConn's PCIe and CXL products and strengthens Marvell's capabilities in scale-up connectivity for next-generation AI and cloud data center architectures. XConn's engineering team and technology will play a key role in advancing Marvell's UALink scale-up switching roadmap as AI systems evolve toward larger, multi-rack deployments. Expected Financial Impact Marvell expect

    2/10/26 5:25:00 PM ET
    $MRVL
    Semiconductors
    Technology

    lululemon Introduces Unrestricted Power™ — A New Sensation for Strength Training

    Unrestricted Power features a new proprietary fabric innovation and performance-led design to deliver an unmatched combination of support, mobility, and on-body feel The training assortment was developed with lululemon Ambassadors, including Lewis Hamilton & Kayla Jeter lululemon (NASDAQ:LULU) today unveiled Unrestricted Power™, a new innovation platform engineered for heavy lifts and demanding gym sessions. The assortment, which launches this morning in North America, is backed by thousands of hours of research and development, providing secure support without compromising comfort and mobility, enabling a distraction-free fit built to match every move. This press release features mult

    2/10/26 8:30:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $BNTX
    $CC
    $ESTC
    $IMGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Auvil Paul R. Iii bought $710,230 worth of Ordinary Shares (10,000 units at $71.02), increasing direct ownership by 36% to 37,956 units (SEC Form 4)

    4 - Elastic N.V. (0001707753) (Issuer)

    12/2/25 4:39:45 PM ET
    $ESTC
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Meintjes Willem A bought $265,302 worth of shares (3,400 units at $78.03), increasing direct ownership by 3% to 132,159 units (SEC Form 4)

    4 - Marvell Technology, Inc. (0001835632) (Issuer)

    9/25/25 11:25:59 AM ET
    $MRVL
    Semiconductors
    Technology

    President, Data Center Group Bharathi Sandeep bought $265,302 worth of shares (3,400 units at $78.03), increasing direct ownership by 5% to 73,392 units (SEC Form 4)

    4 - Marvell Technology, Inc. (0001835632) (Issuer)

    9/25/25 11:24:19 AM ET
    $MRVL
    Semiconductors
    Technology

    $BNTX
    $CC
    $ESTC
    $IMGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BioNTech downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded BioNTech from Outperform to Market Perform and set a new price target of $113.00

    2/2/26 6:48:45 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ulta Beauty upgraded by Raymond James with a new price target

    Raymond James upgraded Ulta Beauty from Outperform to Strong Buy and set a new price target of $790.00

    1/21/26 8:31:04 AM ET
    $ULTA
    Other Specialty Stores
    Consumer Discretionary

    BioNTech upgraded by Goldman with a new price target

    Goldman upgraded BioNTech from Neutral to Buy and set a new price target of $142.00

    1/16/26 8:19:35 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $CC
    $ESTC
    $IMGN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 26, 2024 - FDA Roundup: March 26, 2024

    For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of

    3/26/24 3:38:14 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:

    3/22/24 1:48:21 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ELAHERE issued to IMMUNOGEN INC

    Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:

    11/15/22 5:01:07 PM ET
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BNTX
    $CC
    $ESTC
    $IMGN
    Leadership Updates

    Live Leadership Updates

    View All

    BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

    Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer ("CPO") effective March 1, 2026. The appointment is in line with BioNTech's strategy to become a multi-product oncology company by 2030 and underscores the importance of its global, highly skilled workforce in achieving this objective. In the newly created Management Board role, Kylie Jimenez will be responsible for shaping and leading BioNTech's people strategy and its execution in alignment with the Company's priorities and business goals. She will focus on attractin

    1/28/26 8:00:00 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Victoria's Secret & Co. Reports Third Quarter 2025 Results and Raises Full Year Guidance

    Delivered Net Sales of $1.472 Billion, a 9% Increase Versus Prior Year, Exceeding ExpectationsOperating Results and Earnings Exceed ExpectationsRaises Fiscal Year 2025 Net Sales, Operating Income and Earnings Guidance REYNOLDSBURG, Ohio, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Victoria's Secret & Co. ("VS&Co" or the "Company") (NYSE:VSCO) today reported financial results for the third quarter ended November 1, 2025. Hillary Super, VS&Co Chief Executive Officer, said, "We delivered a standout third quarter, with outperformance on net sales and earnings per share, exceeding the high-end of our guidance. Net sales increased 9% over last year, driven by strength across Victoria's Secret, PINK and

    12/5/25 7:00:00 AM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $BNTX
    $CC
    $ESTC
    $IMGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MarketWise Inc.

    SC 13D/A - MARKETWISE, INC. (0001805651) (Subject)

    11/22/24 11:42:00 AM ET
    $MKTW
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by Victorias Secret & Co.

    SC 13G/A - Victoria's Secret & Co. (0001856437) (Subject)

    11/14/24 4:11:11 PM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by BioNTech SE

    SC 13G/A - BioNTech SE (0001776985) (Subject)

    11/13/24 5:00:57 PM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BNTX
    $CC
    $ESTC
    $IMGN
    Financials

    Live finance-specific insights

    View All

    Victoria's Secret & Co. Invites You to Listen to the Fourth Quarter 2025 Earnings Call

    REYNOLDSBURG, Ohio, Feb. 12, 2026 (GLOBE NEWSWIRE) -- In conjunction with the Victoria's Secret & Co. (NYSE:VSCO) fourth quarter 2025 earnings release, you are invited to listen to a live webcast of the conference call on Thursday, March 5th at 8:30 a.m. ET with Victoria's Secret & Co. executives. The earnings release and related financial information detailing the company's fourth quarter results are expected to be issued approximately one hour prior to the start of the live webcast. The earnings release and related financial information will be available on our website at victoriassecretandco.com/investors. What:Victoria's Secret & Co. Fourth Quarter 2025 Earnings Conference Call Webcast

    2/12/26 7:00:00 AM ET
    $VSCO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Marvell Technology, Inc. Announces Conference Call to Review Fourth Fiscal Quarter and Fiscal Year 2026 Financial Results

    Marvell Technology, Inc. (NASDAQ:MRVL), a leader in data infrastructure semiconductor solutions, today announced it will conduct a conference call following the release of its fourth fiscal quarter and fiscal year 2026 financial results on Thursday, March 5, 2026, at 1:45 p.m. Pacific Time. Conference Call Interested parties may join the live conference call without operator assistance at Call me™ (link will be active approximately 30 minutes before the call) to receive an instant automated callback. To join the call with operator assistance, please dial 1-877-407-8291 or 1-201-689-8345. The call will be webcast and can be accessed at the Marvell Investor Relations website at http://inv

    2/9/26 9:00:00 AM ET
    $MRVL
    Semiconductors
    Technology

    Chemours Announces Dates for Fourth Quarter 2025 Earnings Release and Webcast Conference Call

    WILMINGTON, Del., Feb. 4, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its fourth quarter 2025 financial results after market on Thursday, February 19, 2026. The Company expects to hold its conference call to discuss its fourth quarter 2025 financial results at 8:00 a.m. Eastern Time on Friday, February 20, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of

    2/4/26 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials